A treatment cycle with bevacizumab used off-label costs approximately 20 euros.
Notes on verification
Verbatim claim traces to epicentro.iss.it (Italian public health institute), which itself derives from the AGCM 2014 antitrust ruling against Roche/Novartis. Multiple independent sources (AGCM ruling, TAR Lazio review, parliamentary Q&A, academic commentary) corroborate the same order of magnitude (15-80 euro), though exact framing (per injection vs per cycle) varies slightly across sources.
Sources
- Procedura di infrazione da parte dell'Autorità Antitrust (epicentro.iss.it)
- https://www.agcm.it/dotcmsCustom/getDominoAttach?urlStr=192.168.14.10%3A8080%2F41256297003874BD%2F0%2FAF96880B5B6A7C6FC1257C9F0053DDF3%2F%24File%2Fp24823.pdf (agcm.it)
- https://giustizia-amministrativa.it/portale/pages/istituzionale/ucm?id=KLXH4YK23XCOJXQ4DGNU4U42QM&q= (giustizia-amministrativa.it)
- https://www.camera.it/temiap/t/news/post-OCD15-11543 (camera.it)
- https://www.agcm.it/media/comunicati-stampa/2014/3/alias-6801 (agcm.it)